Resource

Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drug

Miser, William F; Arakaki, Richard; Jiang, Honghua; Scism-Bacon, Jamie; Anderson, Pamela W; Fahrbach, Jessie L
Clinical therapeutics; 2010 May;32(5):896-908. PMID: 20685497
Department of Family Medicine, The Ohio State University College of Medicine, Columbus, Ohio 43201, USA. miser.6@osu.edu
Category: 

Abstract

Insulin glargine and lispro mix 75/25 (75% insulin lispro protamine suspension and 25% insulin lispro injection [LM75/25]) represent 2 common starter insulin regimen classes: basal and premixed. After initiation of starter insulin therapy, if patients with type 2 diabetes mellitus (DM) are unable to achieve a glycosylated hemoglobin (HbA1c) level <7.0%, insulin intensification may be indicated. The DURABLE (Assessing Durability of Basal Versus Lispro Mix 75/25 Insulin Efficacy) trial was designed to compare initiating insulin therapy with analogue basal insulin versus premixed analogue insulin in patients unable to achieve good glycemic control while taking multiple oral antihyperglycemic drugs (OADs).